2.89

0.75% 0.05

OncoCyte Corporation (OCX)

Überblick Nachrichten Preisverlauf Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.84

Offen:

$2.83

24-Stunden-Volumen:

7,206

Relative Volume:

0.09

Marktkapitalisierung:

$81.36M

Einnahmen:

$709.00K

Nettoeinkommen (Verlust:

$-43.14M

KGV:

-0.6366

EPS:

-4.54

Netto-Cashflow:

$-20.35M

1W Leistung:

+0.57%

1M Leistung:

-15.84%

6M Leistung:

-8.29%

1J Leistung:

+14.45%

1-Tages-Spanne:

$2.7801

$2.92

1-Wochen-Bereich:

$2.76

$3.075

52-Wochen-Spanne:

$1.922

$4.75

OncoCyte Corporation Stock (OCX) Company Profile

Firmenname

OncoCyte Corporation

Sektor

Healthcare (1152)

Branche

Biotechnology (660)

Telefon

510-775-0515

Adresse

1010 Atlantic Avenue, Suite 102, Alameda, CA

Mitarbeiter

Twitter

@OncocyteCorp

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

OCX's Discussions on Twitter

Vergleichen Sie OCX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OCX OncoCyte Corporation	2.89	81.36M	709.00K	-43.14M	-20.35M	-4.54
VRTX Vertex Pharmaceuticals Inc	476.54	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	560.51	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	598.41	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	231.24	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.60	26.16B	3.81B	-644.79M	-669.77M	-6.24

OncoCyte Corporation Stock (OCX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-28	Eingeleitet	Lake Street	Buy
2022-05-24	Herabstufung	Stephens	Overweight → Equal-Weight
2022-03-14	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2022-01-07	Eingeleitet	Stephens	Overweight
2022-01-06	Fortgesetzt	Piper Sandler	Overweight
2021-03-17	Fortgesetzt	Needham	Buy
2021-01-07	Hochstufung	The Benchmark Company	Speculative Buy → Buy
2020-12-16	Hochstufung	Piper Sandler	Neutral → Overweight
2020-11-30	Eingeleitet	BTIG Research	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2020-07-30	Bestätigt	The Benchmark Company	Speculative Buy
2020-07-01	Herabstufung	Piper Sandler	Overweight → Neutral
2020-06-30	Herabstufung	Chardan Capital Markets	Buy → Neutral
2020-06-02	Eingeleitet	Needham	Buy
2019-02-13	Eingeleitet	Piper Jaffray	Overweight
2019-01-29	Hochstufung	Janney	Neutral → Buy
2018-12-19	Fortgesetzt	Lake Street	Buy

Alle ansehen

OncoCyte Corporation Aktie (OCX) Neueste Nachrichten

Apr 17, 2025

Oncocyte appoints new independent accounting firm - Investing.com

Apr 17, 2025

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - The Globe and Mail

Apr 17, 2025

Apr 08, 2025

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener

Apr 08, 2025

Apr 07, 2025

OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Apr 07, 2025

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 07, 2025

Apr 04, 2025

OncoCyte Co. (NASDAQ:OCX) Sees Large Increase in Short Interest - Defense World

Apr 04, 2025

Apr 02, 2025

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - TradingView

Apr 02, 2025

Oncocyte Unveils Game-Changing Transplant Diagnostic Technology at Major Healthcare Conference - Stock Titan

Apr 02, 2025

Apr 01, 2025

Lake Street starts OncoCyte coverage with Buy, $5 target By Investing.com - Investing.com Canada

Mar 28, 2025

OncoCyte a new buy at Lake Street on transplant rejection testing - MSN

Mar 28, 2025

OncoCyte’s Strategic Positioning and Growth Potential in Transplant Rejection Testing - TipRanks

Mar 28, 2025

OncoCyte initiated with a Buy at Lake Street - TipRanks

Mar 28, 2025

Lake Street Initiates Coverage on OncoCyte (OCX) with Buy Rating - GuruFocus

Mar 28, 2025

Lake Street starts OncoCyte coverage with Buy, $5 target - Investing.com India

Mar 28, 2025

Mar 26, 2025

OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World

Mar 26, 2025

OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World

Mar 26, 2025

Mar 25, 2025

OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks

Mar 25, 2025

OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo

Mar 25, 2025

Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com Australia

Mar 25, 2025

Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com India

Mar 25, 2025

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025

Needham maintains Buy on OncoCyte, steady $4.25 target By Investing.com - Investing.com South Africa

Mar 25, 2025

Positive Outlook on OncoCyte’s Stock Due to Strategic Launch and Financial Management - TipRanks

Mar 25, 2025

OncoCyte: Q4 Earnings Snapshot - CT Insider

Mar 25, 2025

Oncocyte Corp Reports 2024 Success and 2025 Growth Plans - TipRanks

Mar 25, 2025

Mar 24, 2025

OncoCyte Corp Q4 2024 Earnings: Revenue Surges to $1.5 Million, Beating Estimates; EPS at -0.43 - GuruFocus

Mar 24, 2025

Oncocyte reports progress in organ transplant diagnostics By Investing.com - Investing.com South Africa

Mar 24, 2025

Oncocyte targets $20M in recurring revenue from 20 transplant centers by 2025 - MSN

Mar 24, 2025

Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances By Investing.com - Investing.com South Africa

Mar 24, 2025